Science Intelligence and InfoPros

Little things about Scientitic Watch and Information Professionnals

Posts Tagged ‘Pharma 3.0

Review of my book: Information Today

leave a comment »

by Katherine Allen; From Science 2.0 to Pharma 3.0. Posted on July 29, 2013.

 

“As a librarian in a large pharmaceutical company, Hervé Basset has a perspective both on drug manufacturers and consumers of scientific information. In this book he aims to explore the profound changes that are currently affecting science communication, and the impact that the life sciences industry is having on our society. He draws parallels between the worlds of ‘big pharma’ and ‘big STM publishing’, since both face radical challenges from internet enabled consumers, and both have reason to be wary of the risks posed by new ways of working and communicating. As Basset points out, the two worlds are closely intertwined: “pharma customers represent 20 per cent of big STM sales … Similarly, big pharma is strictly dependent on scientific publishing for the research process, for the update of researchers’ knowledge and for the publicity of their products.”

Read the full article at:

http://www.infotoday.eu/Articles/ReadArticle.aspx?ArticleID=91020

 

Written by hbasset

July 29, 2013 at 6:59 pm

Posted in Science 2.0

Tagged with ,

From Science 2.0 to Pharma 3.0: my interview (Market Intelligence Hub)

leave a comment »

We recently caught up with Hervé Basset, specialist librarian in the pharmaceutical industry and owner of the blog “Science Intelligence“, to talk about the inspiration behind his recent book  entitled “From Science 2.0 to Pharma 3.0″, published by Chandos Publishing and available on Amazon.

Read the full article on http://digimind.com/blog/experts/pharma-3-0/

 

 

Written by hbasset

February 22, 2013 at 7:43 pm

Posted in Pharmaceutical Industry

Tagged with

Pharma 3.0: “a monumental shift is happening” (E&Y)

leave a comment »

A monumental shift is happening that will impact the future of healthcare, according to an Ernst & Young report, which outlines a new approach to healthcare delivery, leading to the reinvention of commercial models within the pharmaceutical industry. (…)

The report, Progressions – The third place: Healthcare everywhere examines how several forces, including patent cliffs; reduced R&D productivity, pricing pressures, globalization and demographics have made the industry’s long-standing blockbuster business model increasingly outdated. These factors fueled a transition known as the move from Pharma 1.0, a vertically integrated blockbuster model to Pharma 2.0, which is the current model based on a more diversified market portfolios and a broader focus on bottom-line returns, not just top-line growth. The move to Pharma 3.0 won’t be automatic. (…)

“What we’re talking about at a very high level is a move to new healthcare system that is based on value and not volume,” (…)

Signs exist indicating that pharma companies are moving customer centricity (…)

Pharma 3.0 is also significant because it involves the transition from blockbuster drugs to more personalized medicine for smaller populations…

Read the full article:

Burns, Mia. Pharma moving toward more customer-centric models. MedAdNews-Pharmalive, online on February, 5th 2013. Available from:
http://blog.medadnews.com/index.php/2013/02/05/pharma-moving-toward-more-customer-centric-models/

For Pharma 3.0 models, read also:

From Science 2.0 to Pharma 3.0

Available at Chandos: http://www.woodheadpublishing.com/en/book.aspx?bookID=2767&ChandosTitle=1

and on Amazon bookstore: http://www.amazon.com/Science-2-0-Pharma-3-0-Pharmaceutical/dp/1843347091/ref=sr_1_1?s=books&ie=UTF8&qid=1355255814&sr=1-1&keywords=basset+chandos

 

 

Written by hbasset

February 6, 2013 at 8:22 pm

Posted in Pharmaceutical Industry

Tagged with

Pharma 3.0: rethinking influence of pharma in patients’ lives

with one comment

Nothing new, but a good paper:

Science, medicine and healthcare have always been collaborative but in recent years this has intensified. The web both encourages powerful networks and makes them easier to explore – whether networks of co-authorship between key opinion leaders, citations between scientific papers or interactions between patients on specialised social networks. 

The web has given us the tools to connect and collaborate. For good or ill, influence nowadays is not always defined by knowledge, experience and authority, but also by how connected and engaged you are.

The importance of networks in healthcare and medicine will only increase. (…)

So what can pharma do to ensure it thrives in this environment?

First of all, it must understand the networks. Listening and profiling exercises can identify where conversations are taking place, what content resonates and how it is being shared.Crucially, there is a need to map the relationships between actors in the network, not just the actors themselves. (…)

But listening is not enough. Pharma must engage, embedding itself in networks and communicating honestly, ethically and as an equal. A strong presence will ensure that a brand’s voice is heard, as will checking that all the touchpoints discovered during the research phase are addressed. (…)

This new, highly networked era is a huge opportunity for pharmaan opportunity to get closer to customers and become a bigger part of their lives. But it’s much more than that. It’s also the best feedback loop we could ever wish for, giving us a chance to understand the impact of our actions on those who matter most – healthcare practitioners and their patients.”

Lamb, Andrew. Rethinking influence in a networked world. PMLive, Published on 2nd of March 2012.
http://www.pmlive.com/pharma_news/rethinking_influence_in_a_networked_world_389326

 

 

 

 

 

 

Written by hbasset

March 5, 2012 at 8:30 pm